Moderna Outlines Pregnancy Outcome Study Details For Its COVID-19 Shot - Moderna (NASDAQ:MRNA), Pfizer (NYSE:PFE), BioNTech (NASDAQ:BNTX)

In a few days, Moderna Inc MRNA will start a trial designed to evaluate pregnancy outcomes in women after receiving the Company's COVID-19 shot during their pregnancy.
According to an update posted on the ClinicalTrials.gov website, the trial will begin on July 22, targeting the enrollment of 1,000 participants.
The observational study with a 21-month follow-up period is expected to complete in January 2024.
During the period, the primary data from pregnant women and their healthcare providers will be collected for the study.
The Centers for Disease Control and Prevention recommended that pregnant females receive the messenger-RNA-based COVID-19 vaccines developed by Pfizer Inc PFE/ BioNTech SE BNTX and Moderna.
Also, Monday, Moderna announced a supply agreement with the government of Argentina for 20 million doses of its COVID-19 vaccine or its updated variant booster vaccine candidate, if authorized.
Delivery will start from 1Q of 2022.
Price Action: MRNA shares are up 3.7% at $241.24 during the market session on the last check Monday.